Results 51 to 60 of about 486,600 (333)

Recommendations for Competency in Allergy Training for Undergraduates Qualifying as Medical Practitioners

World Allergy Organization Journal, 2009
The Council acknowledges specific comments from: The American Academy of Allergy, Asthma and Immunology (AAAAI) (Amal H Assa'ad); The American College of Allergy, Asthma and Immunology (ACAAI) (Mark Dykewicz, D. Betty Lew, Bryan L. Martin); The Argentine
Paul C. Potter, MD, FCPaed(SA), DCH(SA), FAAAAI, FACAAI, John O. Warner, MD, FRCPCH, FMedSci, Ruby Pawankar, MD, PhD, Michael A. Kaliner, MD, Sergio Del Giacco, MD, Lanny Rosenwasser, MD, Karen Henley   +6 more
doaj  

Historical Perspective of Inborn Errors of Immunity in Turkey

Turkish Journal of Immunology
This article details the development of immunology as a scientific discipline based on basic research and clinical application in Turkey. Due to the valiant efforts of the Turkish Society of Immunology (TSI), immunology has become a fundamental ...
Yıldız Camcıoğlu
doaj   +1 more source

A real-world intention-to-treat analysis of a decade’s experience of treatment of hepatitis C with interferon-based therapies [version 1; referees: 2 approved]

F1000Research, 2016
Objectives: To assess the uptake of pegylated interferon (PegIFN) plus ribavirin (RBV)-based regimens in patients with hepatitis C virus (HCV) in a large, single-centre, real-world setting over 10 years.
Nowlan Selvapatt, Ashley Brown
doaj   +1 more source

Gut microbiota diversity is prognostic and associated with benefit from chemo‐immunotherapy in metastatic triple‐negative breast cancer

Molecular Oncology, EarlyView.
We assessed the associations between the gut microbiota and outcome in metastatic triple‐negative breast cancer patients treated with chemotherapy alone or chemotherapy in combination with immunotherapy. Our data indicate that high gut microbiota alpha diversity was associated with improved clinical outcome and with benefit from immunotherapy.
Andreas Ullern, Kristian Holm, Andreas Hagen Røssevold, Nikolai Kragøe Andresen, Corinna Bang, Ole Christian Lingjærde, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +8 more
wiley   +1 more source

A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome

The Journal of Clinical Investigation, 2023
BACKGROUND Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a primary immunodeficiency disorder caused by heterozygous gain-of-function CXCR4 mutations.
David H. McDermott, Daniel Velez, Elena Cho, Edward W. Cowen, John J. DiGiovanna, Diana V. Pastrana, Christopher B. Buck, Katherine R. Calvo, Pamela J. Gardner, Sergio D. Rosenzweig, Pamela Stratton, Melissa A. Merideth, H. Jeffrey Kim, Carmen Brewer, James D. Katz, Douglas B. Kuhns, Harry L. Malech, Dean Follmann, Michael P. Fay, Philip M. Murphy   +19 more
doaj   +1 more source

The accumulation of myeloid‐derived suppressor cells participates in abdominal infection‐induced tumor progression through the PD‐L1/PD‐1 axis

Molecular Oncology, EarlyView.
This study explores how sepsis affects GC progression by creating an immunosuppressive environment. Our findings reveal that sepsis promotes immune dysregulation, enhancing tumor growth and metastasis. Targeting the PD‐1/PD‐L1 pathway with monoclonal antibodies shows potential for restoring immune function and improving outcomes in cancer patients ...
Yiding Wang, Ting Guo, Xiaofang Xing, Xijuan Liu, Xuejun Gan, Yingai Li, Yan Liu, Fei Shan, Zhouqiao Wu, Jiafu Ji, Ziyu Li   +10 more
wiley   +1 more source

A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome

JCI Insight, 2022
BACKGROUND Primary Sjögren’s syndrome (pSS) is characterized by B cell hyperactivity and elevated B-lymphocyte stimulator (BLyS). Anti-BLyS treatment (e.g., belimumab) increases peripheral memory B cells; decreases naive, activated, and plasma B cell ...
Xavier Mariette, Francesca Barone, Chiara Baldini, Hendrika Bootsma, Kenneth L. Clark, Salvatore De Vita, David H. Gardner, Robert B. Henderson, Michael Herdman, Karoline Lerang, Prafull Mistry, Raj Punwaney, Raphaele Seror, John Stone, Paul L.A. van Daele, André van Maurik, Nicolas Wisniacki, David A. Roth, Paul Peter Tak   +18 more
doaj   +1 more source

Polyfunctional CD8+CD226+RUNX2hi effector T cells are diminished in advanced stages of chronic lymphocytic leukemia

Molecular Oncology, EarlyView.
CD226+CD8+ T cells express elevated levels of RUNX2, exhibit higher proliferation capacity, cytokines and cytolytic molecules expression, and migratory capacity. In contrast, CD226−CD8+ T cells display an exhausted phenotype associated with the increased expression of co‐inhibitory receptors and impaired effector functions.
Maryam Rezaeifar, Shima Shahbaz, Anthea C. Peters, Spencer B. Gibson, Shokrollah Elahi   +4 more
wiley   +1 more source

Decoding multicellular interaction networks–a new horizon in tumor microenvironment research

Molecular Oncology, EarlyView.
Cells in the tumor microenvironment influence tumor establishment and progression through an elaborate array of cellular interactions. Integrating transcriptomic, spatial, and intercellular crosstalk data at single‐cell resolution unveil complex, functionally distinct multicellular circuits.
Roi Balaban, Merav Cohen
wiley   +1 more source

Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression

Molecular Oncology, EarlyView.
Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park, Jae Won Oh, Hyewon Chung, Jung Won Kwon, Yi Rang Na, Kwang Pyo Kim, Seung Hyeok Seok   +6 more
wiley   +1 more source